98 related articles for article (PubMed ID: 17387334)
1. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity.
Ramsubir S; Yoshimitsu M; Medin JA
Mol Ther; 2007 Jun; 15(6):1174-81. PubMed ID: 17387334
[TBL] [Abstract][Full Text] [Related]
2. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
3. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
5. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.
Takenaka T; Qin G; Brady RO; Medin JA
Hum Gene Ther; 1999 Aug; 10(12):1931-9. PubMed ID: 10466627
[TBL] [Abstract][Full Text] [Related]
6. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
[TBL] [Abstract][Full Text] [Related]
7. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice.
Pacienza N; Yoshimitsu M; Mizue N; Au BC; Wang JC; Fan X; Takenaka T; Medin JA
Mol Ther; 2012 Jul; 20(7):1454-61. PubMed ID: 22472949
[TBL] [Abstract][Full Text] [Related]
8. Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells.
Liang SB; Yoshimitsu M; Poeppl A; Rasaiah VI; Cai J; Fowler DH; Medin JA
Mol Ther; 2007 Mar; 15(3):618-27. PubMed ID: 17228315
[TBL] [Abstract][Full Text] [Related]
9. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
[TBL] [Abstract][Full Text] [Related]
10. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
11. Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.
Takiyama N; Dunigan JT; Vallor MJ; Kase R; Sakuraba H; Barranger JA
Hum Gene Ther; 1999 Dec; 10(18):2881-9. PubMed ID: 10609650
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
13. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
14. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.
Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577
[TBL] [Abstract][Full Text] [Related]
15. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
Yoshimitsu M; Higuchi K; Fan X; Takao S; Medin JA; Tei C; Takenaka T
Mol Biol Rep; 2011 Jun; 38(5):3145-52. PubMed ID: 20131008
[TBL] [Abstract][Full Text] [Related]
16. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
17. Lentivirus-mediated gene therapy for Fabry disease.
Khan A; Barber DL; Huang J; Rupar CA; Rip JW; Auray-Blais C; Boutin M; O'Hoski P; Gargulak K; McKillop WM; Fraser G; Wasim S; LeMoine K; Jelinski S; Chaudhry A; Prokopishyn N; Morel CF; Couban S; Duggan PR; Fowler DH; Keating A; West ML; Foley R; Medin JA
Nat Commun; 2021 Feb; 12(1):1178. PubMed ID: 33633114
[TBL] [Abstract][Full Text] [Related]
18. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
19. Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene.
Vallera DA; Jin N; Shu Y; Panoskaltsis-Mortari A; Kelekar A; Chen W
Hum Gene Ther; 2003 Dec; 14(18):1787-98. PubMed ID: 14670129
[TBL] [Abstract][Full Text] [Related]
20. Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
Rappa G; Lorico A; Hildinger M; Fodstad Ø; Baum C
Hum Gene Ther; 2001 Sep; 12(14):1785-96. PubMed ID: 11560771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
